1

Title:

Mortality Associated with Proportionality of Secondary Mitral Regurgitation After Transcatheter Mitral Valve Repair: MFIRE Registry

Neal M Duggal MD^a, Milo Engoren MD^a, Scott M Chadderdon MD^b, Evelio Rodriguez MD^c, M Andrew Morse MD^d, Mani A Vannan MD^e, Pradeep K Yadav MD^e, Michael Morcos MD^f, Flora Li MD^g, Mark Reisman MD^h, Enrique Garcia-Sayan MDⁱ, Deepa Raghunathan MDⁱ, Nishtha Sodhi MD^j, Paul Sorajja MD^k, Lily Chen MD^l, Jason H Rogers MD^l, Marcella A Calfon Press MD PhD^m, Christopher P Kovach MDⁿ, Edward A Gill MDⁿ, Firas E Zahr MD^b, Stanley J Chetcuti MD^o, Yuan Yuan MS^a, Graciela B Mentz PhD^a, D Scott Lim MD^j, Gorav Ailawadi MD^p

a Department of Anesthesiology, University of Michigan, Ann Arbor, MI b_{Division of Cardiology, Knight Cardiovascular Institute, Oregon Health and Science University,} Portland, OR c Department of Cardiothoracic Surgery, Ascension Saint Thomas Heart, Nashville, TN ^dDivision of Cardiology, Ascension Saint Thomas Heart, Nashville, TN
^eMareus Heart Valve Center, Riedmant Heart Institute, Atlanta, GA Marcus Heart Valve Center, Piedmont Heart Institute, Atlanta, GA f Division of Cardiology, University of Washington, Seattle, WA g Department of Anesthesiology, University of Washington, Seattle, WA h Division of Cardiology, Weill Cornell Medical Center, NY, NY i Division of Cardiovascular Medicine, University of Texas Health Science Center at Houston, Houston, TX j Division of Cardiovascular Medicine, University of Virginia, Charlottesville, VA k Valve Science Center, Minneapolis Heart Institute, Abbott Northwestern Medical Center, Minneapolis, MN ¹Division of Cardiovascular Medicine, University of California Davis Medical Center, Sacramento, CA mDivision of Cardiology, University of California Los Angeles, Los Angeles, CA ⁿDivision of Cardiology, University of Colorado, Aurora, CO Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI ^pDepartment of Cardiac Surgery, University of Michigan, Ann Arbor, MI Short title: Increased Mortality with Increased Proportionality Total word count: 5000 Corresponding Author: Neal Duggal, MD Department of Anesthesiology, University of Michigan Hospital Division of Cardiothoracic Anesthesia 4172 Cardiovascular Center 1500 E. Medical Center Drive, SPC 5861

Ann Arbor, MI 48105

neald@med.umich.edu

2

Abstract:

BACKGROUND The association, if any, between the effective regurgitant orifice (EROA) to left ventricular end-diastolic volume (LVEDV) ratio and 1-year mortality is controversial in patients undergoing mitral transcatheter edge-to-edge repair (m-TEER) with the MitraClip[™] system. The objective is to determine the association between EROA/LVEDV and 1-year mortality among patients undergoing m-TEER with MitraClip™.

METHODS In patients with severe secondary (functional) mitral regurgitation (MR), we analyzed registry data from 11 centers using generalized linear models with the generalized estimating equations approach.

RESULTS We studied 525 patients with secondary MR who underwent m-TEER in 11 centers. Most patients were male (63%) and were NYHA class III (61%) or IV (21%). MR was caused by ischemic cardiomyopathy in 51% of patients.EROA/LVEDV values varied widely with median=0.19 mm²/mL, interquartile range [0.12,0.28] mm²/mL, and 187 (36%) patients had values ≤ 0.15 mm²/mL. Post-procedural MR severity improved substantially, being 1+ or less in 74%, $2+$ in 20%, $3+$ in 4%, and $4+$ in 2%. 1-year mortality was 22%. After adjustment for confounders, the logarithmic transformation of EROA/LVEDV was associated with 1-year mortality (odds ratio=0.600, 95% confidence interval [0.386,0.933], p=0.023). A higher Society of Thoracic Surgeons risk score was also associated with increased mortality.

CONCLUSIONS Lower values of Ln(EROA/LVEDV) were associated with increased 1-year mortality in a multi-center registry. The slope of the association is steep at low values, but gradually becomes flatter as Ln(EROA/LVEDV) increases.

3

What is Known:

In recent years, mitral transcatheter edge-to-edge repair (m-TEER) approval has expanded to select patients with functional mitral regurgitation.

The paradigm of proportionate and disproportionate MR as measured by EROA/LVEDV has been proposed as a potential rationale to reconcile conflicting trial results.

What the Study Adds:

Before adjustment, EROA/LVEDV was not associated with mortality (0.22 \pm 0.13 vs 0.21 \pm 0.14, $p=0.425$, standardized difference = -0.08).

However, after adjustment we found that the logarithmic transformation of the pre-procedural EROA/LVEDV, Ln(EROA/LVEDV) was associated with 1-year mortality (OR = 0.600 , 95% CI $[0.386, 0.933], p=0.023$.

Progressively higher values of pre-procedural EROA/LVEDV were always associated with a progressively lower odds ratio of death post-procedurally, without a plateau or cutoff but with an "elbow" around 0.15 mm²/mL.

4

Abbreviations:

CI: confidence interval COAPT: Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation EROA: effective regurgitant orifice area FMR: functional mitral regurgitation LVEDV: left ventricular end diastolic volume LVEF: left ventricle ejection fraction M-FIRE: North American Mitraclip for Functional Mitral Regurgitation MR: mitral regurgitation m-TEER: mitral transcatheter edge to edge repair OR: odds ratio TVT: Transcatheter Valve Therapy registry

5

INTRODUCTION

Unlike primary mitral regurgitation (MR), surgical intervention for secondary MR (also known as functional MR) has been shown to increase the quality of life but not extend survival.^{1,2} In these challenging patients transcatheter repair techniques have been explored as alternative treatment options and are preferred in appropriately selected patients. The largest transcatheter experience has been with the mitral transcatheter edge-to-edge leaflet repair (m-TEER) technique with the commercially-available MitraClip® device. In 2013, the FDA approved MitraClip for prohibitive surgical risk patients with primary MR based on the results of the EVEREST Trials and REALISM Registry.³⁻⁶ In 2019, this m-TEER approval was extended to selected patients with significant secondary MR who remain symptomatic despite maximally tolerated guideline-directed medical therapy.⁶

The FDA approval for secondary MR treatment with MitraClip integrates the results of two randomized landmark trials, COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) and MITRA-FR (Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation).^{1,2} However, these trials have shown conflicting results of mitral valve m-TEER in patients with secondary MR and reduced ejection fraction. The MITRA-FR study did not demonstrate a reduction of the primary combined endpoint of allcause death and unplanned hospitalization for heart failure at 1-year follow-up.² In contrast, the COAPT trial demonstrated significant reductions hospitalizations for heart failure and all-cause mortality over a 2-year follow-up. 1

6

The paradigm of proportionate and disproportionate MR has been proposed as a potential rationale to reconcile these conflicting trial results.⁷⁻⁹ This concept suggests that patients enrolled in the MITRA-FR trial had MR severity that was predominantly proportional to the degree of LV enlargement (i.e. "proportionate MR") with a smaller EROA and larger LVEDV leading to a reduced EROA/LVEDV ratio.⁷⁻⁹ In contrast, COAPT had enrolled patients whose effective regurgitant orifice (EROA) was larger but whose LV end-diastolic volumes (LVEDV) were smaller than those in MITRA-FR leading to a higher EROA/LVEDV ratio.⁷⁻⁹ Accordingly, the severity of MR was greater than could be accounted for by the degree of LV dilation (i.e. "disproportionate MR", defined by these authors as an EROA/LVEDV>0.14 mm2/mL).⁷⁻⁹ However, questions have been raised about the volume measurements in the COAPT trial, suggesting an underestimation of LVEDV or an overestimation of the EROA.^{10,11} In addition, this model lacks enough patient-level data.¹² More recently, registry-based studies have failed to show a consistent association between EROA/LVEDV and mortality.¹³⁻¹⁵

Here, we describe the association between MR proportionality, as quantified by the continuous EROA/LVEDV ratio, and mortality among patients with secondary MR and LVEF ≤55% undergoing m-TEER in the North American Mitraclip for Functional Mitral Regurgitation (M-FIRE) registry.

7

METHODS

This is a multi-center retrospective study. This study received a certificate of exemption from the University of Michigan Institutional Review Board (HUM00191906, Ann Arbor, MI). As no patient care interventions were involved, signed patient consent was waived. N Duggal had full access to all the data in the study and takes responsibility for its integrity and the data analysis. We included registry data from 11 MitraClip centers (Appendix 1). We included all adult patients (>18 years) with symptomatic (New York Heart Association II, III, IV) MR assessed by echocardiography within 3-6 months of undergoing m-TEER with the MitraClipTM device, and left ventricular ejection fraction $\leq 55\%$.¹⁶ Patients were excluded if they had concomitant primary/degenerative MR (prolapse/flail leaflets), secondary MR predominantly driven by mitral annular dilatation (atrial FMR) with presence of normal ventricular function, prior mitral valve leaflet surgery, cardiogenic shock requiring need for mechanical support preoperatively, status 1 heart transplant listed or previous heart transplant, or active endocarditis or evidence of intracardiac thrombus.

All studies were interpreted by expert echocardiographers at large, tertiary care institutions, and the severity of MR before and after the intervention was determined based on the multi-parametric approach and quantitation methods recommended by the American Society of Echocardiography guidelines.¹⁶⁻¹⁸ MR was classified using a 4-grade system as recommended by the Mitral Valve Academic Research Consortium: mild $(1+)$, moderate $(2+)$, moderate-severe $(3+)$, or severe $(4+)$.¹⁹ Left ventricular internal dimensions in systole and diastole were obtained via the parasternal long-axis view in transthoracic echocardiograms.. The left ventricular volumetric measurements were obtained using two-dimensional Simpson's method of discs.¹⁷

8

The follow up studies were transthoracic studies and assessment of MR was assessed by postprocedure valvular regurgitation guidelines.¹⁸

DATA COLLECTION

Study data was collected via combined queries from each participating institution's electronic medical record and the Society of Thoracic Surgeons (STS) & American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry from 2014 to 2020. They were then combined into the M-FIRE registry. Within the STS/ACC TVT registry database patient history, demographics, and preoperative echocardiographic, MitraClip procedural, postoperative, and follow-up data are stored as discrete, searchable database concepts. Echocardiographic data were reviewed by each of the participating sites.

STATISTICAL ANALYSIS

For the outcome of 1-year mortality, patients who were alive at 1 year were compared to those who died by 1 year using Fisher's exact test for categorical variables, ANOVA F-test for continuous variables, and standardized differences. P values <0.05 were deemed statistically significant and standardized differences >0.20 or <-0.20 were deemed clinically important. Continuous variables are expressed as mean \pm standard deviation or median [interquartile range]. Next, generalized estimating equations (to account for the clustering within each center) were used to assess associations between EROA/LVEDV and 1-year mortality. Models were adjusted for patient characteristics, STS risk score, and other echocardiographic factors. Coefficients are expressed as odds ratio (OR) and 95% confidence intervals [95% CI]. Continuous variables were assessed for linearity and if nonlinear were transformed as appropriate. Echocardiographic measurements are frequently log-transformed to decrease skew, decrease heteroscedasticity, and

improve model fit.^{20,21} Variables were assessed for collinearity using variance inflation factor >5 and for correlation using Pearson correlation coefficient >0.7.

Missing demographic and cardiac parameters were imputed with chained equations and combined using Rubin's Rules. Missing mortality data were handled in a sensitivity analysis by imputing the outcomes with chained equations. Generalized linear model with the generalized estimating equations approach were conducted as above, with exchangeable correlation matrix and logit link. 95% confidence intervals of the odds ratios that excluded 1 were deemed statistically significant. All statistics were conducted in SAS (SAS Institute, Cary, NC) and SPSS 27 (IBM, Chicago, IL).

POWER ANALYSIS

Assuming 20% mortality, an intracluster correlation $= 0.3$, and 10 participating centers, having 346-379 patients would give us 80% power with alpha = 0.05 to find a change in mortality to 18% for a 20% increase in the EROA/LVEDV ratio and to have 5 predictors in the regression.

10

RESULTS

STUDY POPULATION AND BASELINE CHARACTERISTICS

In eleven American tertiary care heart valve centers, 525 patients were treated with m-TEER for secondary MR between 2014 and 2020 and were included in the M-FIRE registry. After excluding 33 patients (6%) with unknown mortality status, the primary analysis consisted of 492 patients. At one-year follow-up, 108 (22%) had died and 384 (78%) were alive. The baseline characteristics of the patients who were alive or dead at one-year post-procedure are summarized in Tables 1 and 2. The majority of patients were male (63%), with a history of hypertension (84%). Ischemic cardiomyopathy was the most common etiology of MR (51% of patients). Most patients were NYHA functional class III and IV, 61% and 21%, respectively. Pre-procedural MR severity was 3+ in 122 patients (23%) and 4+ in 383 patients (73%) (Table 3). EROA/LVEDV values varied widely with median=0.19, interquartile range [0.12,0.28] mm^2/mL , and 187 (36%) patients had values < 0.15 mm²/mL(Figure 1). Post-procedural MR severity was much improved, being $1+$ or less in 367 patients (74%), $2+$ in 99 patients (20%), $3+$ in 16 patients (3%), and $4+$ in 10 patients (2%).

MORTALITY

There were no differences in patient demographics between those who were alive or dead at one year, however, STS replacement risk $(12.6\% \pm 10.1 \text{ vs } 7.4\% \pm 6.4, \text{ p} < 0.001)$ was higher in the patients who died (Table 2). Univariate analysis revealed that several pre-procedural echocardiographic parameters, such as ejection fraction and right ventricular dysfunction, were significantly associated with 1-year mortality. Notably, EROA/LVEDV was not associated with mortality $(0.22 \pm 0.13 \text{ vs } 0.21 \pm 0.14, \text{p=}0.425, \text{standardized difference} = -0.08)$ (Table 3). Post-

11

procedure, worse MR was associated with increased mortality $1+ [1+,2+]$ vs $1+[1+,1+]$, $p=0.001$, standardized difference=0.50) (Table 3).

Using generalized estimating equations to adjust for confounders, we found that the logarithmic transformation of the pre-procedural EROA/LVEDV, Ln(EROA/LVEDV), was associated with 1-year mortality (OR=0.600, 95% CI [0.386, 0.933], p=0.023) (Table 3). On back-transformation, the odds of dying initially decreased rapidly, but then gradually became less steep. Progressively higher values of pre-procedural EROA/LVEDV were always associated with a progressively lower odds ratio of death post-procedurally, without a plateau or cutoff but with an "elbow" around 0.15 mm²/mL. Using EROA/LVEDV= 0.15 mm²/mL having an OR = 1.0 as the reference, an EROA/LVEDV=0.1 mm²/mL is associated with an 23% [3%, 47%], p<0.001 greater odds of dying (OR=1.23, 95% CI [1.03, 1.47]). At EROA/LVEDV values greater than 0.15 mm²/mL, the OR for mortality is ≤ 1 and decreases more slowly, being 0.70 [0.52,0.95], p<0.001 at an EROA/LVEDV=0.3 mm²/mL and 0.49 [0.27, 0.91], p<0.001 at EROA/LVEDV=0.6 mm²/mL (Graphic Abstract). We also found that having a higher STS replacement risk score (OR=1.09, 95% CI [1.05, 1.13], $p<0.001$), was also independently associated with increased mortality (Table 4).

SENSITIVITY ANALYSIS

To try to determine the possible effect of the 33 (6%) patients missing survival outcomes on our findings, we performed a sensitivity analysis by using multiple imputation. In this analysis we found Ln(EROA/LVEDV) was still associated with 1-year mortality (OR=0.62, 95% CI $[0.40, 0.97]$, p=0.035.

12

DISCUSSION

We found that after adjusting for patient characteristics, STS predicted replacement risk and the echocardiographic measurement of Ln(EROA/LVEDV) was associated with mortality. We found that the association was very steep (Graphic Abstract) at lower values of EROA/LVEDV, but became flatter at higher values, suggestive of an elbow at $\sim 0.15 \text{ mm}^2/\text{mL}$ but no plateau or cutoff. Our findings suggest that despite a good repair, as measured by residual MR and mitral gradient, the pre-m-TEER pathology with patients having lower EROA/LVEDV values have long-lasting effects on mortality. Study is needed to determine how best to treat these high-risk patients. Our findings of an elbow at ~ 0.15 mm²/mL also suggest that the mechanisms associated with MR and m-TEER mortality may differ consistent with the proportionality theory.

Two randomized controlled trials published in 2018 examining m-TEER in patients with chronic heart failure and secondary MR noted conflicting results. In the MITRA-FR trial m-TEER did not reduce the risk of death or hospitalization for heart failure at 2 year follow up. On the contrary, COAPT trial led to significant reduction in mortality and hospitalization for heart failure over the 2 year follow up.^{1,2} Numerous hypotheses have been discussed as plausible explanations for the discordant results of these two trials. In addition to noting the different definitions of severe secondary MR and differences in baseline LV volumes between these trials, there has been much interest in determining whether a severity of MR that is disproportionate to the degree of LV dilatation could predict clinical outcomes. Grayburn et al. developed a pathophysiologic premise that the two trials enrolled different patient populations and that EROA/LVEDV ratio could be useful in clinical decision-making.⁷ They noted in MITRA-FR that MR severity could be explained by the degree of LV enlargement, i.e., proportionate MR

with low EROA/LVEDV which would likely respond to optimization of medical therapy. Whereas, in COAPT, MR severity was much greater than could be accounted for by degree of LV enlargement, i.e., disproportionate MR with high EROA/LVEDV ratios and likely to benefit from m-TEER. These authors designated proportionate MR by an EROA/LVEDV of "roughly ≤ 0.14 to 0.15 mm²/mL" and proposed this metric to help differentiate between disproportionate and proportionate MR.⁷

Several studies investigating this hypothesis, however, have demonstrated limitations on its ability to help identify those patients most likely to benefit from m-TEER. Orban et al. divided the patients in a large multicenter European registry (EuroSMR) of over 1000 patients into tertiles of EROA/LVEDV (<0.115, between 0.115 and 0.165, and \geq 0.165 mm²/mL) and found only a small increased 2-year mortality in the group with $EROA/LVEDV \leq 0.115$ mm²/mL but no difference between the other 2 groups¹³ In a multicenter registry study, Ooms et al. investigated several EROA/LVEDV cutoffs before settling on the median value $0.13 \text{ mm}^2/\text{mL}^{14}$. They found no difference in 2-year mortality between the 2 groups. Similarly, Adamo et al. in a smaller retrospective multicenter registry noted no independent prognostic value in EROA/LVEDV, when dichotomized at the median value 2.25 cm²/L, which is equal to 0.225 mm²/mL.¹⁵ Furthermore, post hoc analysis of MITRA-FR noted neutral impact of m-TEER above and below numerous EROA/LVEDV ratios.²² Lastly, post hoc analysis of COAPT failed to demonstrate that EROA/LVEDV appropriately identified responders to m-TEER.²³ Our study differs from these studies by analyzing EROA/LVEDV as a continuous variable, rather than dichotomizing it. Rarely are there abrupt or dichotomous outcomes from a physiologic parameter. Instead, the probability of the outcome varies smoothly as the physiologic parameter changes. Dichotomizing EROA/LVEDV creates the appearance of an abrupt change at the

14

cutoff, loses information and statistical power (equivalent to losing more than one-third of the patients), and creates false dichotomies, such that all values on the same side of the cutoff have the same risk.²⁴⁻²⁶ Instead, we found that the risk associated with EROA/LVEDV continuously varies, but that the rate at which risk varies depends on the EROA/LVEDV value. At low values of EROA/LVEDV, the change in risk for a given change in EROA/LVEDV is larger than it is at a larger EROA/LVEDV. Hence small differences in measurement of proximal isovelocity surface area (PISA) to estimate EROA will lead to larger changes in estimated risk at low values of EROA/LVEDV than at higher values of EROA/LVEDV.

STUDY LIMITATIONS

First, this is an observational, non-randomized, and retrospective study. As such, we acknowledge the limitations in reporting as well as selection bias. However, the study was conducted in a real world setting where the evaluation and indication for m-TEER was determined by expert heart teams at large experienced tertiary care centers. In addition, all patients were deemed high or prohibitive surgical risk by the local heart team (in contrast to COAPT). With the absence of an independent echocardiography core laboratory, interobserver variability cannot be excluded. However, all measurements were performed by experienced echocardiographers according to the current American Society of Echocardiography guidelines and recommendations.¹⁶⁻¹⁸ In addition, as 3D assessment has better correlation with cardiac MRI, it is possible that 2D LV size and EROA may have been underestimated. Another limitation is that 6% of patients were missing 1-year outcomes. We conducted a sensitivity analysis using imputation and found that the association between Ln(EROA/LVEDV) and 1 year mortality was robust to these missing 33 patients.

STUDY STRENGTHS

The multicenter basis should improve the generalizability of our results. Importantly, rather than just defaulting to a linear relationship between EROA/LVEDV and mortality, we assessed for the shape of the association, which was best with a logarithmic transformation. This is similar to other studies of echocardiographic measurements that also used logarithmic transformations.^{20,21}

CONCLUSIONS

Using the M-FIRE registry, we demonstrated that proportionality, as defined by EROA/LVEDV, provides prognostication of mortality risk after m-TEER. We found that the association was very steep (Graphic Abstract) at lower values of EROA/LVEDV, became flatter at higher values, but without a plateau or cutoff. Our findings contribute to the ongoing debate while providing new insights. Equally, our findings call for further investigation in prospective studies. In conclusion, we found that lower values of Ln(EROA/LVEDV) are associated with higher 1 year mortality.

16

Acknowledgments:

No additional acknowledgements.

Sources of Funding:

No forms of financial support were involved in the work

Disclosures:

Christopher P Kovach MD – No disclosures to report.

D Scott Lim MD – Dr Lim receives institutional grants from Abbott, Boston Scientific, Corvia, Edwards, Medtronic, and Trisol. He is a consultant for Philips, Valgen, and Venus.

Deepa Raghunathan MD – No disclosures to report.

Edward A Gill MD – No disclosures to report.

Enrique Garcia-Sayan MD – No disclosures to report.

Evelio Rodriguez MD – Dr. Rodriguez is a consultant and speaker for Abbott. He receives research funding from Abbott.

Firas E Zahr MD – Dr. Zahr is a consultant and on the advisory board for Medtronic. He receives educational and research grants from Medtronic and Edwards. He receives educational grants from Siemens.

Flora M Li MD – No disclosures to report.

Gorav Ailawadi MD – Dr. Ailawadi is a consultant for Medtronic, Abbott, Edwards, Gore, Anteris, Atricure, CryoLife, Philips, Johnson & Johnson

Graciela B Mentz PhD – No disclosures to report.

Jason H Rogers MD – Dr. Rogers receives research/institutional grants from Abbott and Boston Scientific. He is a consultant for Abbott, Baylis, and Boston Scientific.

Lily Chen MD – Dr. Chen is a consultant for Philips, Abbott, and Akura Medical.

M Andrew Morse MD – Dr Morse previously served as a consultant for Abbott.

Mani A Vannan MD – Dr Vannan receives research support and speakers bureau from Abbott – all payments to the Piedmont Heart Institute, not to self.

Marcella A Calfon Press MD, PhD – No disclosures to report.

Mark Reisman MD – No disclosures to report.

Michael Morcos MD – No disclosures to report.

Milo C Engoren MD – No disclosures to report.

Neal M Duggal MD – No disclosures to report

Nishtha Sodhi MD – Dr. Sodhi is a consultant for Medtronic and Boston Scientific.

Paul Sorajja MD – Dr. Sorajja is a consultant for 4C Medical, Anteris, Abbott Structural, Boston Scientific, Edwards Lifesciences, Evolution Medical, Foldax, GLG, Medtronic, Phillips, Siemens, Shifamed, WL Gore, vDyne, xDot.

Pradeep K Yadav MD – Dr. Yadav is consultant and speaker for Edwards Lifesciences, Abbott Vascular, Boston Scientific. He sits on the advisory board for Dasi Simulations.

Scott M Chadderdon MD – Dr Chadderdon is a consultant for Medtronic and Edwards. He receives a research grant from GE Healthcare.

Stanley J Chetcuti MD – Dr. Chetcuti is a consultant for Medtronic and Boston Scientific. He receives research grants from Jena, Abbott, Edwards, Gore , Medtronic and Boston Scientific.

Yuan Yuan MS – No disclosures to report.

REFERENCES

1. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, et al. Transcatheter mitral-valve repair in patients with heart failure. *N Engl J Med*. 2018;379:2307–2318.

2. Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, Lefèvre T, Piot C, Rouleau F, Carrié D, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. *N Engl J Med*. 2018;379:2297–2306.

3. Feldman T, Kar S, Rinaldi M, Fail P, Hermiller J, Smalling R, Whitlow PL, Gray W, Low R, Herrmann HC, et al. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. *J Am Coll Cardiol*. 2009;54:686–694.

4. George JC, Varghese V, Dangas G, Feldman TE. Percutaneous mitral valve repair: lessons from the EVEREST II (Endovascular Valve Edge-to-Edge REpair Study) and beyond. *J Am Coll Cardiol Intv*. 2011;4:825–827.

5. Feldman T, Kar S, Elmariah S, Smart SC, Trento A, Siegel RJ, Apruzzese P, Fail P, Rinaldi MJ, Smalling RW, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. *J Am Coll Cardiol*. 2015;66:2844–2854.

6. Bonow RO, O'Gara PT, Adams DH. 2019 AATS/ACC/SCAI/STS Expert consensus systems of care document: operator and institutional recommendations and requirements for transcatheter mitral valve intervention: A Joint report of the American Association for Thoracic Surgery, the

American College of Cardiology, the Society for Cardiovascular Angiography and Interventions, and The Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2020;76:96-117.

7. Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT Trials. *JACC Cardiovasc Imaging*. 2019;12:353-362.

8. Grayburn PA, Sannino A, Packer M. Distinguishing proportionate and disproportionate subtypes in functional mitral regurgitation and left ventricular systolic dysfunction. *JACC Cardiovasc Imaging*. 2021;14:726-729.

9. Packer M, Grayburn PA. New evidence supporting a novel conceptual framework for distinguishing proportionate and disproportionate functional mitral regurgitation. *JAMA Cardiol*. 2020;5:469-475.

10. Hagendorff A, Doenst T, Falk V. Echocardiographic assessment of functional mitral regurgitation: opening Pandora's box? *ESC Heart Fail*. 2019;6:678-685.

11. Hagendorff A, Knebel F, Helfen A, Stöbe S, Doenst T, Falk V. Disproportionate mitral regurgitation: another myth? A critical appraisal of echocardiographic assessment of functional mitral regurgitation. *Int J Cardiovasc Imaging*. 2021;37:183-196

12. Resor CD, Brovman EY. Is MitraClip patient selection based on proportionate or disproportionate mitral regurgitation: a proportional response to existing data? *J Cardiothor Vasc Anesth*. 2020;34(6):1688-1689.

13. Orban M, Karam N, Lubos E, Kalbacher D, Braun D, Deseive S, Neuss M, Butter C, Praz F, Kassar M, et al. Impact of proportionality of secondary mitral regurgitation on outcome after transcatheter mitral valve repair. *JACC Cardiovasc Imaging*. 2021;14:715-725.

14. Ooms JF, Bouwmeester S, Debonnaire P, Nasser R, Voigt JU, Schotborgh MA, Geleijnse ML, Kardys I, Spitzer E, Daemen J, et al. Transcatheter edge-to-edge repair in proportionate versus disproportionate functional mitral regurgitation. *J Am Soc Echocardiogr*. 2022;35:105- 115.e8.

15. Adamo M, Cani DS, Gavazzoni M, Taramasso M, Lupi L, Fiorelli F, Giannini C, Branca L, Zuber M, Curello S, et al. Impact of disproportionate secondary mitral regurgitation in patients undergoing edge-to-edge percutaneous mitral valve repair. *EuroIntervention*. 2020;16:413-420.

16. Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, Hahn RT, Han Y, Hung J, Lang RM, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. *J Am Soc Echocardiogr*. 2017;30:303-371.

17. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28:1-39.e14.

18. Zoghbi WA, Asch FM, Bruce C, Gillam LD, Grayburn PA, Hahn RT, Inglessis I, Islam AM, Lerakis S, Little SH, et al. Guidelines for the evaluation of valvular regurgitation after

21

percutaneous valve repair or replacement: A report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Japanese Society of Echocardiography, and Society for Cardiovascular Magnetic Resonance. *J Am Soc Echocardiogr*. 2019;32:431-475. Erratum in: *J Am Soc Echocardiogr*. 2019;32:914-917.

19. Stone GW, Vahanian AS, Adams DH, Abraham WT, Borer JS, Bax JJ, Schofer J, Cutlip DE, Krucoff MW, Blackstone EH, et al. Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: a consensus document from the Mitral Valve Academic Research Consortium. *J Am Coll Cardiol*. 2015;66:278-307.

20. Genovese D, Muraru D, Marra MP, Carrer A, Previtero M, Palermo C, Tarantini G, Parati G, Iliceto S, Badano LP. Left atrial expansion index for noninvasive estimation of pulmonary capillary wedge pressure: a cardiac catheterization validation study. *J Am Soc Echocardiogr*. 2021;34:1242-1252.

21. Dallaire F, Slorach C, Hui W, Sarkola T, Friedberg MK, Bradley TJ, Jaeggi E, Dragulescu A, Har RL, Cherney DZ, et al. Reference values for pulse wave Doppler and tissue Doppler imaging in pediatric echocardiography. *Circ Cardiovasc Imaging*. 2015;8:e002167.

22. Messika-Zeitoun D, Iung B, Armoiry X, Trochu JN, Donal E, Habib G, Brochet E, Thibault H, Piriou N, Cormier B, et al. Impact of mitral regurgitation severity and left ventricular remodeling on outcome after MitraClip implantation: Results from the Mitra-FR Trial. *JACC Cardiovasc Imaging*. 2021;14:742-752.

23. Grayburn PA, Sannino A, Cohen DJ, Kar S, Lim DS, Mishell JM, Whisenant BK, Rinaldi MJ, Kapadia SR, Rajagopal V, et al. Predictors of clinical response to transcatheter reduction of secondary mitral regurgitation: The COAPT Trial. *J Am Coll Cardiol*. 2020;76:1007-1014.

24. Altman DG, Royston P. The cost of dichotomising continuous variables. *BMJ*. 2006;332:1080.

25. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. *Stat Med.* 2006;25:127-141.

26. Austin PC, Brunner LJ. Inflation of the type I error rate when a continuous confounding variable is categorized in logistic regression analyses. *Stat Med.* 2004;23:1159-1178.

Figure Legends

Figure 1. Histogram showing the frequencies of the effective regurgitant orifice area divided by the left ventricular end diastolic volume (EROA/LVEDV) sizes. Median=0.19 and interquartile range [0.12, 0.28] mm²/mL. 187 (36%) patients had values < 0.15 mm²/mL

Graphic Abstract. The Association of EROA/LVEDV with Mortality. Plot of the adjusted odds ratios associated (solid line) with 95% confidence intervals (dashed lines) with EROA/LVEDV=0.15 as the reference showing the risk of death increases as EROA/LVEDV decreases. The plot is back transformed from Ln(EROA/LVEDV).

	All $(n=525)$		Alive $(n=384)$		Died $(n=108)$			
Factor								
	$\mathbf n$	$\frac{0}{0}$	$\mathbf n$	$\frac{0}{0}$	$\mathbf n$	$\frac{0}{0}$	StandDiff	P-value
Male	328	63	236	61	73	68	-0.13	0.261
Diabetes mellitus	182	35	132	34	38	35	0.02	0.909
Hypertension	439	84	333	87	81	75	-0.28	0.010
Previous myocardial infarction	250	48	182	47	54	50	0.05	0.664
Previous percutaneous coronary intervention	202	39	149	39	42	39	0.00	0.999
Previous coronary artery bypass grafting	171	33	120	31	41	38	0.14	0.202
Previous stroke	74	14	59	15	14	13	-0.07	0.646
COPD	195	37	138	36	48	44	0.17	0.118
History of atrial fibrillation or atrial flutter	313	60	231	60	68	63	0.06	0.656
Ischemic mitral regurgitation*	269	51	186	48	66	61	0.26	0.022
Pacemaker/Cardiac resynchronization therapy	192	37	138	36	41	41	0.12	0.311
Internal defibrillator	238	45	174	46	49	49	0.05	0.662
New York Heart Association Class							0.25	0.278
	6		6	$\overline{2}$	$\overline{0}$	$\boldsymbol{0}$		
\mathbf{I}	89	17	65	17	12	11		
III	319	61	231	61	69	64		
IV	111	21	78	21	26	24		

Table 1. Patient Characteristics – Categorical Factors

Thirty-three patients are missing 1 year outcome. Data are missing for 1 patient for sex, diabetes mellitus, hypertension, previous percutaneous coronary intervention, previous coronary artery bypass grafting, previous stroke, and history of atrial fibrillation or atrial flutter, 4 for previous myocardial infarction and ischemic mitral regurgitation, 6 for New York Heart Association class, and 9 for COPD. *included 2 with mixed ischemic/non-ischemic etiology. COPD-chronic obstructive pulmonary disease. StandDiffstandardized difference.

Factor	All $(N=525)$		Alive $(n=384)$		Died $(n=108)$			
	Mean	SD	Mean	SD	Mean	SD	StandDiff	P-value
Age (yr)	71	13	71	12	72	13	0.14	0.202
Height (cm)	171		171	11	172		0.15	0.184
Weight (kg)	79	21	80	21	78	18	-0.07	0.534
Body Mass Index (kg/m^2)	27.0	6.0	27.2	6.1	26.3	5.5	-0.16	0.154
Creatinine (mg/dL)	1.7	1.5	1.7	1.9	2.1	1.9	0.29	0.004
STS Replacement risk $(\%)$	8.8	7.8	7.4	6.4	12.6	10.1	0.61	< 0.001

Table 2. Patient Characteristics -Continuous Factors.

Thirty-three patients are missing 1 year outcome. Data are missing for 3 patients for age, 8 for height, 1 weight, 1 creatinine, and 47 STS replacement risk score. SD-standard deviation. StandDiff-standardized difference. STS Replacement-Society of Thoracic Surgeons risk estimate of mortality with a mitral valve replacement.

	All		Alive		Died			
Factor	$(n=525)$		$(n=384)$		$(n=108)$			
	$\mathbf n$	$\frac{0}{0}$	$\mathbf n$	$\frac{0}{0}$	$\mathbf n$	$\frac{0}{0}$	StandDiff	P-value
Mitral regurgitation severity							0.14	0.595
		0.2	$\mathbf{1}$	0.3	$\boldsymbol{0}$	$\boldsymbol{0}$		
\mathbf{I}	19	4	12	3	6	6		
III	122	23	90	23	25	23		
IV	383	73	281	73	77	71		
	Mean	SD	Mean	SD	Mean	SD	StandDiff	P-value
LVEDV (mL)	201	84	199	81	209	89	0.12	0.238
EROA (cm ²)	0.38	0.18	0.38	0.19	0.38	0.16	-0.08	0.501
$EROA/LVEDV$ (mm ² /mL)	0.22	0.15	0.22	.13	0.21	0.14	-0.09	0.425
Ln(EROA/LVEDV)	-1.68	0.59	-1.66	0.57	-1.74	0.59	-0.13	0.223
LVESV (mL)	139	69	136	67	147	73	0.16	0.138
Ejection fraction $(\%)$	0.32	0.10	0.33	.10	0.31	.10	-0.27	0.040
Discharge MV gradient (mmHg)	$\overline{4}$	$\overline{2}$	4	$\overline{2}$	5	$\overline{2}$	0.15	0.179
	Median	IQR	Median	IQR	Median	IQR	StandDiff	P-value
$EROA/LVEDV$ (mm ² /mL)	0.19	0.12, 0.28	0.19	0.13, 0.28	0.17	0.11, 0.24	-0.08	0.107
Ln(EROA/LVEDV)	-1.68	$-2.10, -1.29$	-1.66	$-2.00, -1.28$	-1.76	$-2.17, -1.42$	-0.09	0.107
TR severity	$\overline{2}$	1, 3	$\overline{2}$	1, 3	3	1, 3	0.31	0.136
RV dysfunction		0, 2		0, 2		0.5, 2	0.39	0.007
Post MR severity		1, 1.5		1, 1	$\mathbf{1}$	1, 2	0.50	0.001
Post MV gradient (mmHg)	3	2, 4	$\overline{3}$	2, 4	$\overline{3}$	2, 5	0.23	0.049
Discharge MR severity		1, 2		1, 1.5		1, 2	0.41	0.001

Table 3. Patient Echocardiography Measurements

Data are missing for 18 patients for discharge MV gradient, 8 RV dysfunction, 1 post MR severity, and 14 discharge MR severity. EROA-estimated regurgitant orifice area. IQR-interquartile range. Ln(EROA/LVEDV)-natural logarithm of estimated regurgitant orifice area/left ventricular end-diastolic volume. LVEDV-left ventricular end-diastolic volume. LVESV-left ventricular end-systolic volume. MR-mitral valve regurgitation. MV-mitral valve. RV-right ventricle. SD-standard deviation. StandDiff-standardized difference. TR-tricuspid valve regurgitation.

28

Table 4. Factors Associated with 1 Year Mortality

Parsimonious Logistic regression showing the factors independently associated with death at 1 year follow-up. COPD-chronic obstructive pulmonary disease. Ln(EROA/LVEDV)-natural logarithm of estimated regurgitant orifice area/left ventricular end-diastolic volume. NYHA-New York Heart Association. STS-Society of Thoracic Surgeons.

